Role of MetallothioneinlH in Cisplatin Resistance of Non-Small Cell Lung Cancer Cells

被引:0
|
作者
Xin-fang Hou~(1*)
2 Cancer Center of Zhengzhou University
Department of Oncology
3 Department of Etiology and Carcinogenesis
机构
关键词
Metallothionein; MT1H; Non-small-cell lung cancer; Drug resistance; Apoptosis;
D O I
暂无
中图分类号
R734.2 [肺肿瘤];
学科分类号
100214 ;
摘要
Objective:Despite platinum-based adjuvant chemotherapy has improved greatly patients’ outcomes,drug resistance poses a major impediment to the successful use of such an effective agent.Metallothioneins(MTs) are known to play putative roles in cancer cell proliferation,apoptosis,differentiation,drug resistance and prognosis. The present studiy was to investigte the role of metallethioein1H(MT1H) in cisplatin resistance of human non-small cell lung cancer(NSCLC) cell lines in vitro or its possible molecular mechanisms. Methods:MT1H mRNA expression in A549 and A549/DDP cells was detected by RT-PCR.A recombinant eukaryotic expression plasmid pcDNA3.1(-)-MT1H was constructed and transfected into A549 cells which express no MT1H.MT1H siRNA was transfected into A549/DDP cells which express MT1H highly.MT1H expression was detected by RT-PCR and Immunoblot.The chemosensitivity to cisplatin was assessed by MTT assay.Apoptosis rate was determined by Tunel and FCM.Bcl-2 and Bax were determined by immunohistochemistry. Results:MT1H mRNA was expressed in A549/DDP but not in A549.After transfection of MT1H,MT1H expression was enhanced and the chemosensitivity to cisplatin was decreased in A549 cells.Inversely,after transfection of MT1H siRNA,MT1H expression was decreased and the chemosensitivity to cisplatin was increased in A549/DDP.The apoptosis rate induced by cisplatin was increased and Bcl-2 was down-regulated but Bax showed little change in A549/DDP cells interferred with MT1H siRNA. Conclusion:MT1H overexpression can promote drug resistance in A549 cells.Down-regulation of MT1H interfered with siRNA can effectively reverses the drug resistance in A549/DDP cells by down-regulating the expression of Bcl-2 and increasing cisplatin induced apoptosis.SiRNA targeting MT1H combined with chemotherapy may be a very promising strategy for treatment of lung cancer.
引用
收藏
页码:247 / 254
页数:8
相关论文
共 50 条
  • [1] Role of metallothionein1h in cisplatin resistance of non-small cell lung cancer cells
    Hou, Xin-fang
    Fan, Qing-xia
    Wang, Liu-xing
    Lu, Shi-xin
    [J]. CHINESE JOURNAL OF CANCER RESEARCH, 2009, 21 (04) : 247 - 254
  • [2] Role of 14-3-3σ in resistance to cisplatin in non-small cell lung cancer cells
    Cetintas, Vildan Bozok
    Tetik, Asli
    Cok, Gursel
    Kucukaslan, Ali Sahin
    Kosova, Buket
    Gunduz, Cumhur
    Veral, Ali
    Eroglu, Zuhal
    [J]. CELL BIOLOGY INTERNATIONAL, 2013, 37 (01) : 78 - 86
  • [3] Exploration of Novel Cisplatin Resistance Factors in Non-Small Cell Lung Cancer Cells
    Suzuki, Toshihiro
    Kato, Moeka
    Miyauchi, Mai
    Ogasawara, Yuki
    [J]. CANCER SCIENCE, 2023, 114 : 1495 - 1495
  • [4] Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer
    Kang-Seo Park
    Hyun-Kyoung Kim
    Jung-Hwa Lee
    Yong-Bock Choi
    Seong-Yeol Park
    Sei-Hoon Yang
    Soo-Youl Kim
    Kyeong-Man Hong
    [J]. Journal of Cancer Research and Clinical Oncology, 2010, 136 : 493 - 502
  • [5] Inflammatory meditated mechanisms of cisplatin resistance in non-small cell lung cancer
    O'Byrne, K.
    Ryan, S-L.
    Heavey, S.
    Umezawa, K.
    Barr, M. P.
    Gray, S. G.
    Davies, A.
    Richard, D.
    Gately, K.
    Baird, A-M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S84 - S84
  • [6] Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer
    Park, Kang-Seo
    Kim, Hyun-Kyoung
    Lee, Jung-Hwa
    Choi, Yong-Bock
    Park, Seong-Yeol
    Yang, Sei-Hoon
    Kim, Soo-Youl
    Hong, Kyeong-Man
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (04) : 493 - 502
  • [7] Expression of multidrug resistance proteins and accumulation of cisplatin in human non-small cell lung cancer cells
    Ikuta, K
    Takemura, K
    Sasaki, K
    Kihara, M
    Nishimura, M
    Ueda, N
    Naito, S
    Lee, E
    Shimizu, E
    Yamauchi, A
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2005, 28 (04) : 707 - 712
  • [8] A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer
    Ramisetty, Sravani
    Kulkarni, Prakash
    Bhattacharya, Supriyo
    Nam, Arin
    Singhal, Sharad S.
    Guo, Linlin
    Mirzapoiazova, Tamara
    Mambetsariev, Bolot
    Mittan, Sandeep
    Malhotra, Jyoti
    Pisick, Evan
    Subbiah, Shanmuga
    Rajurkar, Swapnil
    Massarelli, Erminia
    Salgia, Ravi
    Mohanty, Atish
    [J]. JOURNAL OF CLINICAL MEDICINE, 2023, 12 (02)
  • [9] Intrapleural combination bevacizumab with cisplatin therapy for non-small cell lung cancer caused by non-small cell lung cancer
    Du, Nan
    Zhao, Hui
    Wang, Haibin
    Li, Xiaosong
    Ma, Junxun
    Fan, Zhongyi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] CDKN1A upregulation and cisplatin-pemetrexed resistance in non-small cell lung cancer cells
    Zamagni, Alice
    Pasini, Alice
    Pirini, Francesca
    Ravaioli, Sara
    Giordano, Emanuele
    Tesei, Anna
    Calistri, Daniele
    Ulivi, Paola
    Fabbri, Francesco
    Foca, Flavia
    Delmonte, Angelo
    Molinari, Chiara
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2020, 56 (06) : 1574 - 1584